203 related articles for article (PubMed ID: 11257264)
1. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin.
Turban S; Fuentes F; Ferlic L; Brugada R; Gotto AM; Ballantyne CM; Marian AJ
Atherosclerosis; 2001 Feb; 154(3):633-40. PubMed ID: 11257264
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study.
Sing K; Ballantyne CM; Ferlic L; Brugada R; Cushman I; Dunn JK; Herd JA; Pownall HJ; Gotto AM; Marian AJ
Atherosclerosis; 1999 Jun; 144(2):435-42. PubMed ID: 10407505
[TBL] [Abstract][Full Text] [Related]
3. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
Marian AJ; Safavi F; Ferlic L; Dunn JK; Gotto AM; Ballantyne CM
J Am Coll Cardiol; 2000 Jan; 35(1):89-95. PubMed ID: 10636265
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy.
Ballantyne CM; Herd JA; Stein EA; Ferlic LL; Dunn JK; Gotto AM; Marian AJ
J Am Coll Cardiol; 2000 Nov; 36(5):1572-8. PubMed ID: 11079660
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy.
Elghannam H; Tavackoli S; Ferlic L; Gotto AM; Ballantyne CM; Marian AJ
J Mol Med (Berl); 2000; 78(10):562-8. PubMed ID: 11199329
[TBL] [Abstract][Full Text] [Related]
6. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin.
Salek L; Lutucuta S; Ballantyne CM; Gotto AM; Marian AJ
J Mol Med (Berl); 2002 Nov; 80(11):737-44. PubMed ID: 12436350
[TBL] [Abstract][Full Text] [Related]
7. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis.
Cahilly C; Ballantyne CM; Lim DS; Gotto A; Marian AJ
Circ Res; 2000 Mar; 86(4):391-5. PubMed ID: 10700443
[TBL] [Abstract][Full Text] [Related]
8. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy.
Lutucuta S; Ballantyne CM; Elghannam H; Gotto AM; Marian AJ
Circ Res; 2001 May; 88(9):969-73. PubMed ID: 11349008
[TBL] [Abstract][Full Text] [Related]
9. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
[TBL] [Abstract][Full Text] [Related]
10. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
Herd JA; Ballantyne CM; Farmer JA; Ferguson JJ; Jones PH; West MS; Gould KL; Gotto AM
Am J Cardiol; 1997 Aug; 80(3):278-86. PubMed ID: 9264419
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men.
Malin R; Knuuti J; Janatuinen T; Laaksonen R; Vesalainen R; Nuutila P; Jokela H; Laakso J; Jaakkola O; Solakivi T; Lehtimäki T
J Mol Med (Berl); 2001 Aug; 79(8):449-58. PubMed ID: 11511975
[TBL] [Abstract][Full Text] [Related]
12. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
Herd JA
Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
[TBL] [Abstract][Full Text] [Related]
13. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis.
Chen SN; Ballantyne CM; Gotto AM; Marian AJ
BMC Cardiovasc Disord; 2009 Jan; 9():3. PubMed ID: 19173706
[TBL] [Abstract][Full Text] [Related]
14. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
15. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
[TBL] [Abstract][Full Text] [Related]
16. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients.
Ombres D; Pannitteri G; Montali A; Candeloro A; Seccareccia F; Campagna F; Cantini R; Campa PP; Ricci G; Arca M
Arterioscler Thromb Vasc Biol; 1998 Oct; 18(10):1611-6. PubMed ID: 9763534
[TBL] [Abstract][Full Text] [Related]
17. R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects.
Kuremoto K; Watanabe Y; Ohmura H; Shimada K; Mokuno H; Daida H
J Atheroscler Thromb; 2003; 10(2):85-92. PubMed ID: 12740482
[TBL] [Abstract][Full Text] [Related]
18. PON1 M/L55 mutation protects high-risk patients against coronary artery disease.
Oliveira SA; Mansur AP; Ribeiro CC; Ramires JA; Annichino-Bizzacchi JM
Int J Cardiol; 2004 Mar; 94(1):73-7. PubMed ID: 14996478
[TBL] [Abstract][Full Text] [Related]
19. The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study.
Senti M; Tomás M; Elosual R; Sala J; Masiá R; Marrugat J
Clin Chem Lab Med; 2002 Jul; 40(7):677-83. PubMed ID: 12241013
[TBL] [Abstract][Full Text] [Related]
20. Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease.
Guzmán EC; Hirata MH; Quintão EC; Hirata RD
Clin Chem Lab Med; 2000 Aug; 38(8):731-6. PubMed ID: 11071065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
